Form 13-F position report

RANI THERAPEUTICS HLDGS INC

Reported by MORGAN STANLEY

RANI CUSIP 753018100 Manager CIK 0000895421

Reported 31,155 shares, up 670 (2.2%) from the prior quarter.

Reported value 6.3%; share count 2.2% vs. the prior quarter.

Added
% of reported 13F value < 0.01% This manager · Q3 2026
Shares 31,155 Quarter-end amount reported
Reported value $24,643 Fair value at quarter end
Consecutive quarters held 20 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 61000
2022-03-31 44000
2022-06-30 43000
2022-09-30 44000
2022-12-31 12804
2023-03-31 2735
2023-06-30 7869
2023-09-30 1958
2023-12-31 17267
2024-03-31 7623
2024-06-30 11214
2024-09-30 11342
2024-12-31 8905
2025-03-31 18377
2025-06-30 3607
2025-09-30 3374
2025-12-31 38714
2026-03-31 17906
2026-06-30 23181
2026-09-30 24643

Quarterly position history

How this manager's reported quarter-end position changed over time.

20 quarters
Quarterly reported position history for RANI THERAPEUTICS HLDGS INC held by MORGAN STANLEY.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Added 31,155 +670 (2.2%) < 0.01% $24,643 2026-11-13
Q2 2026 Added 30,485 +6,116 (25.1%) < 0.01% $23,181 2026-08-13
Q1 2026 Reduced 24,369 -4,307 (-15.0%) < 0.01% $17,906 2026-05-15
Q4 2025 Added 28,676 +21,926 (324.8%) < 0.01% $38,714 2026-02-13
Q3 2025 Reduced 6,750 -269 (-3.8%) < 0.01% $3,374 2025-11-14
Q2 2025 Reduced 7,019 -7,566 (-51.9%) < 0.01% $3,607 2025-08-15
Q1 2025 Added 14,585 +8,085 (124.4%) < 0.01% $18,377 2025-05-15
Q4 2024 Added 6,500 +1,249 (23.8%) < 0.01% $8,905 2025-02-14
Q3 2024 Added 5,251 +2,300 (77.9%) < 0.01% $11,342 2024-11-14
Q2 2024 Added 2,951 +500 (20.4%) < 0.01% $11,214 2024-08-14
Q1 2024 Reduced 2,451 -2,750 (-52.9%) < 0.01% $7,623 2024-05-15
Q4 2023 Added 5,201 +4,301 (477.9%) < 0.01% $17,267 2024-02-13
Q3 2023 Reduced 900 -1,010 (-52.9%) < 0.01% $1,958 2023-11-15
Q2 2023 Added 1,910 +1,380 (260.4%) < 0.01% $7,869 2023-08-14
Q1 2023 Reduced 530 -1,640 (-75.6%) < 0.01% $2,735 2023-05-15
Q4 2022 Reduced 2,170 -2,394 (-52.5%) < 0.01% $12,804 2023-02-14
Q3 2022 Added 4,564 +466 (11.4%) < 0.01% $44,000 2022-11-14
Q2 2022 Added 4,098 +820 (25.0%) < 0.01% $43,000 2022-08-15
Q1 2022 Reduced 3,278 -495 (-13.1%) < 0.01% $44,000 2022-05-13
Q4 2021 New 3,773 +3,773 (0.0%) < 0.01% $61,000 2022-02-14

Who else reported the position

75 managers reported RANI THERAPEUTICS HLDGS INC for Q3 2026.

Managers reporting RANI THERAPEUTICS HLDGS INC in Q3 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
Samsara BioCapital LLC Unchanged 10,369,159 0 0.78% $8,202,005 4 qtrs
RA CAPITAL MANAGEMENT L P Unchanged 8,500,000 0 0.07% $6,723,500 4 qtrs
AWM Investment Company Inc Unchanged 7,500,000 0 0.57% $5,932,500 4 qtrs
VANGUARD CAPITAL MANAGEMENT LLC Added 4,566,458 +3,473 < 0.01% $3,612,068 3 qtrs
Longaeva Partners L P Unchanged 2,329,459 0 0.04% $1,842,602 4 qtrs
Polar Asset Management Partners Inc Reduced 2,000,000 -318,542 0.03% $1,582,000 2 qtrs
Siren L L C Reduced 1,594,800 -405,200 0.03% $1,261,487 4 qtrs
GSA CAPITAL PARTNERS LLP Added 1,049,321 +799,605 0.05% $830,000 3 qtrs
MILLENNIUM MANAGEMENT LLC New 968,531 +968,531 < 0.01% $766,108 4 qtrs
HEIGHTS CAPITAL MANAGEMENT INC Unchanged 934,580 0 0.15% $739,253 2 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
November 13, 2026
Filing type
13F-HR
Position type
COM CL A

Voting authority reported

Sole
9,065
Shared
0
None
22,090

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.